No Data
Protara Therapeutics To Host Conference Call And Webcast To Review New Interim Data From Phase 2 ADVANCED-2 Trial Of TARA-002 In Patients With NMIBC On December 5, 2024 At 8:30 A.m. ET
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
Protara Therapeutics Reports Increased R&D Expenses
Oppenheimer Maintains Protara Therapeutics(TARA.US) With Buy Rating, Cuts Target Price to $25
Oppenheimer Sticks to Their Buy Rating for Protara Therapeutics (TARA)
Protara Therapeutics | 8-K: Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
No Data
No Data
